Cordyceps : le guide de référence

Résumé PubMed complet

Cordyceps militaris is an edible medicinal fungus with potential metabolic benefits, but its effects on type 2 diabetes mellitus accompanied by hyperlipidaemia (T2DM-HLP) remain incompletely understood. This study evaluated the effects of orally administered C. militaris ethanol extract (EAE; 2.0 g kg-1) and cordycepin (50 or 100 mg kg-1) in a T2DM-HLP mouse model over 6 weeks. Metabolic indices, serum transaminases, colon and liver histology, gut bacterial and fungal communities, serum metabolites, and FXR/TGR5-related molecular markers were assessed. Compared with the model group, EAE and 50 mg kg-1 cordycepin reduced serum lipid and transaminase levels to varying degrees and were associated with downward shifts in fasting blood glucose and oral glucose tolerance test curves. Histological alterations in the colon and liver were also less apparent in these two groups. Faecal 16S rDNA and ITS sequencing showed changes in the bacterial and fungal community structure, while untargeted serum metabolomics identified distinct metabolic profiles involving bile acids, fatty acids, amino acids, nucleotides, and redox-related metabolites. Enrichment analyses implicated bile secretion, primary bile acid biosynthesis, cholesterol metabolism, cAMP signalling, and amino acid metabolism. These changes were accompanied by increased colonic TGR5 and hepatic FXR immunoreactivity, increased hepatic Fxr, Nr0b2, and Ppara expression, and reduced Cyp7a1 expression. Responses to 100 mg kg-1 cordycepin were less consistent, indicating no simple dose-dependent relationship under the present conditions. Overall, EAE and cordycepin were associated with improved metabolic status and coordinated changes in the gut microbial composition, serum metabolism, and bile acid-related molecular readouts.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Shi H, Meng Y, Zhang G, Ling J
Revue : Food & function
Publication : 2026-09-04 · PMID 42695401 · DOI 10.1039/d6fo02540d

Résumé PubMed complet

As a rare and precious traditional Chinese medicine (TCM), Ophiocordyceps sinensis (O. sinensis) is plagued by various adulterants in the market due to factors such as resource scarcity, which seriously affects medication safety and clinical efficacy. Existing identification methods generally have problems including strong subjectivity, high sample destructiveness, long detection cycle, and complex operation, and it is difficult to identify different types of adulterants using the same method. Innovatively, this study adopted scanning electron microscopy-energy dispersive x-ray spectroscopy (SEM-EDS) technology to establish a rapid, accurate, and widely applicable method for identifying adulterated O. sinensis. Authentic O. sinensis samples from major producing areas such as Xizang, Qinghai, Sichuan, and Gansu, as well as different types of adulterated samples, were collected. Using SEM-EDS technology, combined with micromorphology and elemental composition, the differences between authentic and adulterated samples were systematically revealed through indicators including morphological differences, mass fraction of characteristic elements, and surface area coverage (SAC) of characteristic elements in surface scanning. This study confirmed that SEM-EDS technology could simultaneously obtain the micromorphological and elemental distribution information of samples, realizing rapid and accurate identification of multiple types of adulterated O. sinensis. The proposed method provided new technical support for the quality control and market supervision of O. sinensis, which could be extended to the adulteration inspection of other precious and delicate TCM.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Liu YW, Nie LX, Wu Y, Qian ZM, Guo K, Li Z, Zhang Y, Yu JD, et al.
Revue : Microscopy research and technique
Publication : 2026-09-02 · PMID 42683766 · DOI 10.1002/jemt.70171

Résumé PubMed complet

Increasing exposure to blue light has raised concern about retinal injury, particularly in retinal pigment epithelial (RPE) cells. N-retinylidene-N-retinylethanolamine (A2E), a photosensitive fluorophore associated with age-related macular degeneration, is an important mediator of this process. In this study, feature-based molecular networking guided the identification of cordylutenes A-J (1-10), a new molecular family of blue light-protective fungal pigments from Cordyceps militaris. These metabolites possess a previously unreported symmetric all-E C20 polyene dicarbonyl skeleton with carotenoid-like UV absorption. They were characterized at the molecular-family level by shared UV features and diagnostic, internally consistent MS2 fragmentation patterns. Cordylutenes A (1) and B (2) were isolated as representative members for structural characterization. In an A2E-mediated blue-light injury model in ARPE-19 cells, the cordylutene complex (CCL, 1 μg/mL) and cordylutene A (1, 0.1 μg/mL) improved cell viability to 84.78 ± 4.02% and 92.14 ± 1.88%, respectively, and reduced intracellular oxidative stress to 63.67 ± 3.33% and 43.89 ± 9.59%, respectively. These findings identify cordylutenes as a new family of fungal pigments with protective effects in an A2E-mediated photo-oxidative retinal cell injury model.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Wu HC, Gu A, Chang YL, Lu CK, Lee YC, Yu PW, Lee TH
Revue : Journal of natural products
Publication : 2026-08-28 · PMID 42424532 · DOI 10.1021/acs.jnatprod.6c00427

Résumé PubMed complet

Background:Cordyceps militaris (C. militaris) is a medicinal mushroom recognized for its diverse pharmacological activities, largely attributed to its principal bioactive nucleosides, cordycepin and adenosine. Although accumulating evidence supports their neuroprotective potential, the molecular mechanisms underlying their effects against Alzheimer's disease (AD) remain incompletely understood. This study investigated the neuroprotective effects of cordycepin and adenosine against amyloid-β (Aβ42)-induced neurotoxicity and explored their potential molecular mechanisms using integrated experimental and computational approaches. Methods: SH-SY5Y neuroblastoma cells were pretreated with cordycepin (COR), adenosine (ADE), or donepezil (DNPZ) prior to Aβ42 exposure, and cell viability was assessed using the MTT assay. Drug-likeness and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties were evaluated in silico, followed by network pharmacology to identify potential therapeutic targets and enriched biological pathways. Molecular docking and molecular dynamics simulations were performed to elucidate the interactions of the compounds with selected Alzheimer's disease-related proteins. Results: COR and ADE significantly attenuated Aβ42-induced cytotoxicity and improved SH-SY5Y cell viability. Network pharmacology identified 84 shared molecular targets, including 9 AD-associated genes. Protein-protein interaction analysis revealed hub genes involved in signal transduction, epigenetic regulation, and purine metabolism, while Gene Ontology and KEGG enrichment analyses highlighted pathways associated with neuroactive ligand-receptor interaction, calcium signaling, and inflammatory regulation. ADMET analysis predicted favorable pharmacokinetic properties for both compounds, although cordycepin was predicted to be AMES-positive. Molecular docking and molecular dynamics simulations demonstrated stable interactions of COR and ADE with liver X receptors (LXRα and LXRβ), whereas donepezil exhibited stronger binding affinity toward β-secretase (BACE1). Conclusions: COR and ADE exert neuroprotective effects through coordinated modulation of multiple AD-related signaling pathways rather than a single molecular target. These findings provide mechanistic insights into the neuroprotective activities of C. militaris-derived nucleosides and support further investigation of their potential as multi-target therapeutic candidates for AD and other neurodegenerative disorders.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Thoe ES, Tan HD, Fauzi A, Chamyuang S, Tang YQ, Chia AYY
Revue : Biomedicines
Publication : 2026-08-20 · PMID 42652243 · DOI 10.3390/biomedicines14081862

Résumé PubMed complet

Non-small cell lung cancer (NSCLC) accounts for the highest cancer-related mortality worldwide. Chemotherapy, the backbone of treatment for advanced disease, is constrained by drug resistance and off-target toxicity. Extracts of Cordyceps sinensis (CORS), a medicinal fungus, contain cordycepin, cordyceps polysaccharides (CSP), and various sterols that suppress NSCLC cell proliferation and induce apoptosis in preclinical models. Translating these findings to the clinic, however, faces three problems. First, the active compounds are poorly absorbed orally. Second, water-based decoction inevitably co-extracts inorganic arsenic at roughly four times the Chinese Pharmacopoeia limit. Third, CORS components lack tumor-targeting capability. We propose combining purified cordycepin and CSP with magnetic PLGA-PEG nanoparticles loaded with superparamagnetic iron oxide (SPIO), using an external magnet to concentrate the nanoparticles at the tumor and focused ultrasound to do two things at once: mechanically disrupt the polymer matrix to release the drug payload, and where a sonosensitizer is co-loaded, generate cytotoxic reactive oxygen species (ROS). We also address a practical hurdle: ultrasound attenuates massively in aerated lung. We review workarounds including endobronchial ultrasound, lower frequencies, and microbubble-enhanced cavitation. Compared with immune checkpoint inhibitors, which require PD-L1 positivity and carry a risk of serious immune-related adverse events, our platform operates through multi-targeted mechanisms independent of a single biomarker. Sonodynamic ROS may also induce immunogenic cell death, suggesting potential synergy with immunotherapy.In our view, this nano-enabled approach to traditional Chinese medicine represents one way to bring the pharmacology of CORS into the era of evidence-based oncology.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Zhang Z, Huang C, Ling X, Gan X, Zheng Q, Zhang B, Li J, Wang L
Revue : International journal of nanomedicine
Publication : 2026-08-20 · PMID 42639578 · DOI 10.2147/IJN.S632002

Résumé PubMed complet

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible interstitial lung disease that severely impairs patients' quality of life and overall survival, yet few therapeutic drugs are available for this disease. Cordyceps militaris (L.) Link. is an edible and medicinal fungus renowned for its lung- and kidney-nourishing properties. Decoctions containing C. militaris and other traditional Chinese medicines have been used clinically to treat elderly patients with IPF. Nevertheless, whether C. militaris or its derived products can suppress the progression of pulmonary fibrosis remains unclear. This study aimed to evaluate the effect of a granule formulation prepared from the aqueous extract of C. militaris (CC) on pulmonary fibrosis. An HPLC-UV method was used for the quantification of five major nucleosides in CC and its ethanol extract (CCE, with maltodextrin removed). Two pulmonary fibrosis cellular models were utilized to evaluate the bioactivity of CCE, including TGF-β1-stimulated BEAS-2B human bronchial epithelial cells and A549 human lung adenocarcinoma epithelial cells. A bleomycin-induced mouse model of pulmonary fibrosis was established to evaluate in vivo efficacy of CC. Western blot and RT-qPCR were performed to quantify the protein and mRNA expression levels of key biomarkers associated with epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) deposition in pulmonary fibrosis, including E-cadherin, N-cadherin, vimentin, α-SMA, fibronectin, collagen I and collagen III. Non-invasive whole-body plethysmography (WBP) was used to measure pulmonary function parameters in mice. The contents of uridine, guanosine, adenosine, cordycepin, and N6-(2-hydroxyethyl)adenosine were 0.84, 0.56, 0.93, 1.56 and 1.15 mg/g in CC and 4.49, 1.71, 3.96, 5.57 and 4.79 mg/g in CCE, respectively, with the total nucleoside content being 5.04 and 20.52 mg/g. CCE (200-800 μg/mL) dose-dependently inhibited the mRNA and protein expression of fibronectin, collagen I, and collagen III (ECM-related markers) in TGF-β1-stimulated BEAS-2B cells, whereas CCE upregulated E-cadherin mRNA and protein expression (EMT-related marker) in TGF-β1-treated A549 cells. In bleomycin-challenged mice, intragastric administration of CC at 600 mg/kg reduced lung hydroxyproline level, mitigated elevated enhanced pause (Penh), and markedly downregulated the protein expression of fibronectin, collagen I and collagen III. In vitro and in vivo studies indicated that CC and CCE alleviated pulmonary fibrosis, which associated with reduced EMT/ECM marker expression, in particular inhibiting overproduction of ECM components (fibronectin, collagen I, and collagen III). C. militaris granules represent a potential anti-fibrotic candidate that merits further preclinical investigation.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Ji X, Chen K, Liu S, Jin M, Chen Y, Bai H, Feng M, Liu C, et al.
Revue : Journal of ethnopharmacology
Publication : 2026-08-11 · PMID 42580541 · DOI 10.1016/j.jep.2026.122295

Résumé PubMed complet

Cordyceps militaris polysaccharides (CMPs) are food-relevant bioactive macromolecules attracting increasing interest in functional foods, nutrition, and health-promoting agricultural products. This review summarizes recent advances in the extraction, purification, structural characterization, biological activities, structure-activity relationships, safety evaluation, pharmacokinetics, potential applications, and bibliometric trends of CMPs. Current evidence shows that the monosaccharide composition, molecular weight, glycosidic linkages, branching degree, and conformational features of CMPs are closely associated with their antioxidant, immunomodulatory, anti-inflammatory, lipid-lowering, glucose-regulating, gut microbiota-modulating, and other health-related activities. These properties support the potential use of CMPs as natural ingredients for functional foods, nutritional products, feed additives, and food-related biomaterials. However, further progress is limited by insufficient standardization of extraction and purification methods, incomplete structural elucidation, limited pharmacokinetic and digestion data, and a lack of clinical validation. In particular, the scarcity of long-term safety data and a poor understanding of the oral absorption, metabolic fate, and systemic bioavailability of CMPs represent critical bottlenecks that must be resolved before translational development can proceed. This review provides a scientific basis for the quality control, functional evaluation, and food-oriented application of CMPs while underscoring the urgent need for rigorous safety and pharmacokinetic investigations to support their future development in nutrition and agricultural product sectors. © 2026 Society of Chemical Industry.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Wang P, Li H, Wang Z, Liu H, Chen G, Xu G, Zhang R, Liao Y
Revue : Journal of the science of food and agriculture
Publication : 2026-07-28 · PMID 42521464 · DOI 10.1002/jsfa.70921

Résumé PubMed complet

Wild Chinese Cordyceps polysaccharides (CPs) exert immunomodulatory effects that are closely associated with their structural characteristics. However, research on its structure-function relationship remains limited. This work aims to compare the immunological efficacy of CPs with different molecular weights (MW), together with characterizing their structures and exploring the potential mechanisms of the isolated components. Four CPs with varying MWs were extracted by a stepwise ethanol precipitation technique and subsequently purified through column chromatography. They were named CP-20-1a, CP-40-2a, CP-60-2, and CP-80-2 in descending order of MW. The immunomodulatory effects of these CPs were evaluated using a cyclophosphamide (CTX)-induced immunosuppression mouse model. Among them, CP-20-1a, possessing the largest MW, had the most potent immunomodulatory activity, primarily modulating CD4+ T cells. Structural analysis revealed that CP-20-1a is a branched α-D-glucan with a → 4)-α-D-Glc-(1→/→4,6)-α-D-Glc-(1 → backbone and O-6-linked α-D-Glc-(1 → or α-D-Glc-(1 → 3)-α-D-Glc-(1 → branches. In vitro investigations based on fluorescent labeling demonstrated that CP-20-1a predominantly accumulated on the cell membrane of CD4+ T cells. Transcriptomic analysis and Western blot results demonstrated that CP-20-1a reinstated T lymphocyte proliferation through the Frizzled/AKT/β-catenin pathway along with mTOR signaling, thereby fulfilling its immunomodulatory role. In conclusion, these findings elucidated the chemical foundation underlying the immunomodulatory activity of CPs and provide a foundation for developing targeted immune-regulatory agents in subsequent studies.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Cordyceps ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Ruan Y, Bian Z, Li Y, Fang J, Zhao A, Sun S, Yue X, He L, et al.
Revue : International journal of biological macromolecules
Publication : 2026-07-25 · PMID 42498196 · DOI 10.1016/j.ijbiomac.2026.153692